Nocturia is a condition that is characterized by the need of more than one times micturition per night. The disease is divided into two categories, lower urinary tract dysfunction, and upper urinary tract dysfunction. Nocturia is also considered as a symptom associated with overactive bladder and benign prostate obstruction. Nocturia generally occurs to older people (greater than 65 years of age). Certain risk factors that can cause nocturia in both men and women are caffeine, diuretics medications, excessive fluids before bedtime, alcohol, and pathological conditions such as metabolic disease, sleep disorders, prostatic disease, and anxiety. According to researchers, the condition can also arise from cardiovascular disease, stroke, myeloneuropathy and peripheral oedema. Wellesley Pharmaceuticals, LLC is in the process of developing paxerol as a cyclooxygenase inhibitor and prostaglandin inhibitor for the treatment of nocturia. Ferring Pharmaceuticals, Inc. is in the process of developing desmopressin as a vasopressin receptor agonist for the treatment of nocturia. Some of the companies having the pipeline of nocturia include Wellesley Pharmaceuticals, LLC, Ferring Pharmaceuticals, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.